{
}
Canada is piloting an incentive program to combat antimicrobial resistance (AMR), with other nations like the UK and Japan exploring similar initiatives. Experts emphasize the need for a unified scientific approach to address AMR, highlighting the importance of prevention, regulation, and understanding community needs to ensure effective antibiotic use and animal health. Access to antibiotics is improving in low- and middle-income countries, but these regions are becoming hotspots for AMR, necessitating urgent action.
The pharmaceutical and chemical sector constitutes about 40% of Swiss exports, with major companies like Roche and Novartis closely monitoring the implications of a potential second Trump presidency. While there are hopes for biomedical innovation, concerns about public trust in the industry and the impact of proposed healthcare policies loom large, especially regarding drug pricing and the role of scientific research. Trump's administration may also challenge global health initiatives and partnerships, particularly with China, complicating the landscape for Swiss pharmaceutical firms reliant on international trade.
Nations have established the "Cali Fund" to ensure companies sharing profits from genetic resources contribute to biodiversity preservation, targeting firms with significant revenues. However, the voluntary nature of contributions raises concerns about the impact on rapid vaccine development and access to genetic data, particularly amid ongoing pandemic negotiations. Critics warn that new regulations could hinder medical research, emphasizing the need for seamless access to digital sequence information for effective health responses.
David Reddy
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
global efforts to combat antimicrobial resistance through incentives and collaboration
Canadian Dollar
Japanese Yen
United States Dollar
British Pound Sterling
Euro
Aurobac Therapeutics
Pfizer Inc.
BEAM Alliance
GBR
CAN
ITA
JPN
SAU
Arshnee Moodley
Tamas Koncz
Khumbize Kandodo Chiponda
John-Arne Røttingen
David Reddy
Show more
21:23 14.11.2024
Trump presidency poses risks and opportunities for Swiss pharmaceutical industry
United States Dollar
Hoffmann-La Roche AG
Novartis AG
Bayer
CHE
USA
CHN
David Reddy
Elon Musk
Robert F. Kennedy Jr.
Sebastian Guth
Kamala Harris
Show more
16:00 08.11.2024
nations agree on biodiversity fund amid challenges for developing countries
United States Dollar
International Bank For Reconstruction And Development - World Bank Trust Funds
IFPMA
Moderna, Inc.
Pfizer Inc.
BioNTech
USA
FRA
NOR
GBR
AUT
David Reddy
Colman O’Criodain
Inger Andersen
Kirsten Schuijt
Show more
23:27 04.11.2024
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Global Trade Developments
Stock Market Updates
Retail and Consumer Goods
Supply Chain Management
Industry Mergers & Acquisitions
Private Equity Deals
Fintech Startups
Government Economic Policies
Venture Capital Investments
Inflation and Monetary Impact
CEO Changes
Central Bank Actions
Workplace Trends
Corporate Social Responsibility
Finance Mergers & Acquisitions
Economic Indicators
AI Innovations
Countries:
Companies:
Apple Inc.
Google Inc.
Grab2Go AS
OLA ELECTRIC MOBILITY LTD
EFG Hermes Egypt
Delhivery Limited
Ecom Express Ltd.
NIO Inc.
Morgan Stanley
Nikkei 225
Nintendo Co., Ltd.
Goto Ltd
Mizuho Financial Group, Inc.
Mitsubishi UFJ Financial Group, Inc.
Microsoft Corporation
Scripbox.COM India Ltd.
Amazon.com, Inc.
OpenAI ERC USD
FTSE NASDAQ Dubai UAE 20 Index
JPMorgan Chase & Co.
Currencies:
United States Dollar
Indian Rupee
Euro
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
Egyptian Pound
South Korean Won
Indonesian Rupiah
Saudi Riyal
Pakistani Rupee
Hong Kong Dollar
New Taiwan Dollar
Offshore Chinese Yuan
Qatari Riyal
Malaysian Ringgit
Filipino Peso
West African CFA Franc
Thai Baht
Mexican Peso
People: